Navabi H - Search Results

1

Generation of in vitro autologous human cytotoxic T-cell response to E7 and HER-2/neu oncogene products using ex-vivo peptide loaded dendritic cells.

Navabi H, Jasani B, Adams M, Evans AS, Mason M, Crosby T, Borysiewicz L. Navabi H, et al. Adv Exp Med Biol. 1997;417:583-9. doi: 10.1007/978-1-4757-9966-8_94. Adv Exp Med Biol. 1997. PMID: 9286422 No abstract available.

2

Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer.

Adams M, Borysiewicz L, Fiander A, Man S, Jasani B, Navabi H, Lipetz C, Evans AS, Mason M. Adams M, et al. Among authors: navabi h. Vaccine. 2001 Mar 21;19(17-19):2549-56. doi: 10.1016/s0264-410x(00)00488-6. Vaccine. 2001. PMID: 11257391 Review.

3

Clinical studies of human papilloma vaccines in cervical cancer.

Adams M, Borysiewicz L, Fiander A, Man S, Jasani B, Navabi H, Evans AS, Mason M. Adams M, et al. Among authors: navabi h. Adv Exp Med Biol. 2001;495:419-27. doi: 10.1007/978-1-4615-0685-0_61. Adv Exp Med Biol. 2001. PMID: 11774604 No abstract available.

4

Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R).

Adams M, Navabi H, Jasani B, Man S, Fiander A, Evans AS, Donninger C, Mason M. Adams M, et al. Among authors: navabi h. Vaccine. 2003 Jan 30;21(7-8):787-90. doi: 10.1016/s0264-410x(02)00599-6. Vaccine. 2003. PMID: 12531360 Review.

5

Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial.

Navabi H, Croston D, Hobot J, Clayton A, Zitvogel L, Jasani B, Bailey-Wood R, Wilson K, Tabi Z, Mason MD, Adams M. Navabi H, et al. Blood Cells Mol Dis. 2005 Sep-Oct;35(2):149-52. doi: 10.1016/j.bcmd.2005.06.008. Blood Cells Mol Dis. 2005. PMID: 16061407

6

A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro.

Navabi H, Jasani B, Reece A, Clayton A, Tabi Z, Donninger C, Mason M, Adams M. Navabi H, et al. Vaccine. 2009 Jan 1;27(1):107-15. doi: 10.1016/j.vaccine.2008.10.024. Epub 2008 Oct 31. Vaccine. 2009. PMID: 18977262

7

Role of calcium chelation in high-temperature antigen retrieval at different pH values.

Morgan JM, Navabi H, Jasani B. Morgan JM, et al. Among authors: navabi h. J Pathol. 1997 Jun;182(2):233-7. doi: 10.1002/(SICI)1096-9896(199706)182:2<233::AID-PATH827>3.0.CO;2-Y. J Pathol. 1997. PMID: 9274536

8

Analysis of antigen presenting cell derived exosomes, based on immuno-magnetic isolation and flow cytometry.

Clayton A, Court J, Navabi H, Adams M, Mason MD, Hobot JA, Newman GR, Jasani B. Clayton A, et al. Among authors: navabi h. J Immunol Methods. 2001 Jan 1;247(1-2):163-74. doi: 10.1016/s0022-1759(00)00321-5. J Immunol Methods. 2001. PMID: 11150547

9

The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer.

Adams M, Navabi H, Croston D, Coleman S, Tabi Z, Clayton A, Jasani B, Mason MD. Adams M, et al. Among authors: navabi h. Vaccine. 2005 Mar 18;23(17-18):2374-8. doi: 10.1016/j.vaccine.2005.01.014. Vaccine. 2005. PMID: 15755631

10

Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.

Jasani B, Navabi H, Adams M. Jasani B, et al. Among authors: navabi h. Vaccine. 2009 May 26;27(25-26):3401-4. doi: 10.1016/j.vaccine.2009.01.071. Epub 2009 Feb 5. Vaccine. 2009. PMID: 19200817

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

22 results

Search Page

Filters